Burning Rock Biotech is a holding company. Through its subsidiaries, Co. engages in the developing and providing cancer therapy selection tests. Co.'s next-generation sequencing(NGS)-based cancer therapy selection test products are used to assist in selecting the therapy for cancer patients. Co. provides NGS-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples. Co.'s products, including OncoCompass™ IO, OncoScreen™ IO and OncoCompass™ Target. We show 1 historical shares outstanding datapoints in our coverage of BNR's shares outstanding history.
Understanding the changing numbers of BNR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BNR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BNR by allowing them to research BNR shares outstanding history
as well as any other stock in our coverage universe. |
Free BNR Email Alerts:
Video: Shares Outstanding Importance
